Online Exclusive Article

Relationship Between Severity of Symptoms and Quality of Life in Patients With Breast Cancer Receiving Adjuvant Hormonal Therapy

Leah Ochayon

Revital Zelker

Luna Kaduri

Ilana Kadmon

symptom alleviation, hormone therapy, quality of life
ONF 2010, 37(5), E349-E358. DOI: 10.1188/10.ONF.E349-E358

Purpose/Objectives: To describe symptoms and quality of life (QOL) of patients with breast cancer receiving adjuvant hormonal therapy and to examine possible relationships between the two measurements.

Design: Descriptive, correlational study.

Setting: An oncology clinic within a tertiary medical center in Israel.

Sample: Convenience sample of 132 patients diagnosed with primary breast cancer receiving hormonal therapy.

Methods: Data collection was conducted through the self-administered Functional Assessment of Cancer Therapy endocrine subscale and a sociodemographic and medical information questionnaire.

Main Research Variables: QOL and symptoms of hormonal therapy.

Findings: Ten symptoms were categorized by more than 20% of the participants as "very much" or "quite a bit." The mean QOL score for the participants was higher than that for a healthy population, although a correlation was found between fewer symptoms and higher QOL. Mood swings and irritability were the symptoms most strongly associated with a decrease in QOL. Patients who exercised had higher QOL scores.

Conclusions: Adjuvant hormonal therapy did not affect the QOL of a majority of patients with primary breast cancer. A reduced number of symptoms indicated a higher QOL. Mood swings and irritability have a negative impact on QOL.

Implications for Nursing: A need exists to design a program to follow up on hormonal symptoms and the QOL of patients receiving hormonal therapy and to encourage patients to engage in regular exercise.

Jump to a section

    References

    Alfano, C. M., McGregor, B. A., Kuniuki, A., Reeve, B. B., Bowen, D. J., Baumgartner, K. B., … McTiernan, A. (2006). Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psycho-Oncology, 15, 985-1000. doi: 10.1002/pon.1033
    ATAC Trialists' Group. (2004). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of five years' adjuvant treatment for breast cancer. Retrieved from http://image.thelancet.com/extras/04/et1112web.pdf
    ATAC Trialists' Group. (2006). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncology, 7, 633-643. doi: 10.1016/S1470-2045(06)70767-7
    Avis, N. E., Crawford, S., & Manuel, J. (2005). Quality of life among younger women with breast cancer. Journal of Clinical Oncology, 23, 3322-3330. doi: 10.1200/JCO.2005.05.130
    Badger, T., Braden, C. J., & Mishel, M. H. (2001). Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer. Oncology Nursing Forum, 28, 567-574.
    Barron, T. I., Connoly, R. M., Bennett, K., Feely, J., & Kennedy, M. J. (2007). Early discontinuation of tamoxifen: A lesson for oncologists. Cancer, 109, 832-839. doi: 10.1002/cncr.22485
    Big 1-98 Collaborative Group. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353, 2747-2757.
    Biglia, N., Cozzarella, M., Cacciari, F., Ponzone, R., Maggiorotto, F., & Sismondi, P. (2003). Menopause after breast cancer: A survey on breast cancer survivors. Maturitas, 45, 29-38. doi: 10.1016/S0378-5122(03)00087-2
    Blackledge, G., Baum, M., Vander Bogaret, W., Dwlozier, T., Denton, S., Fallowfield, L., … Veyret, C. (1998). Living with advanced breast cancer hormone treatment: The nurse's perspective. European Journal of Cancer Care, 7, 113-119. doi: 10.1046/j.1365-2354.1998.00076.x
    Brucker, P. S., Yost, K., Cashy, J., Webster, K., & Cella, D. (2005). General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Evaluation and the Health Professions, 28, 192-211. doi: 10.1177/0163278705275341
    Buzdar, A. (2003). Arimidex® (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer—Efficacy overview. Journal of Steroid Biochemistry and Molecular Biology, 86, 399-403. doi: 10.1016/S0960-0760(03)00350-9
    Buzdar, A. (2004). Hormonal therapy in early and advanced breast cancer. Breast Journal, 10(Suppl. 1), S19-S21. doi: 10.1111/j.1524-4741.2004.101S7.x
    Carpenter, J. S. (2005). State of the science: Hot flashes and cancer, part 1: Definition, scope, impact, physiology, and measurement. Oncology Nursing Forum, 32, 959-968. doi: 10.1188/05.ONF.959-968
    Carpenter, J. S., & Andrykowski, M. A. (1999). Menopausal symptoms in breast cancer survivors. Oncology Nursing Forum, 26, 1311-1317.
    Carpenter, J. S., Johnson, D. H., Wagner, L. J., & Andrykowski, M. A. (2002). Hot flashes and related outcomes in breast cancer survivors and matched comparison women [Online exclusive]. Oncology Nursing Forum, 29, E16-E25. doi: 10.1188/02.ONF.E16-E25
    Casso, D., Buist, D. S., & Taplin, S. (2004). Quality of life of 5-10 year breast cancer survivors diagnosed between age 40 and 49. Health and Quality of Life Outcomes, 2(25), 1-9.
    Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., … Brannon, J. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570-579.
    Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., & Fisher, B. (1999). Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project p-1 study. Journal of Clinical Oncology, 17, 2659-2669.
    Dodd, M. J., Miaskowski, C., & Paul, S. M. (2001). Symptom clusters and their effect on the functional status of patients with cancer. Oncology Nursing Forum, 28, 465-470.
    Dow, K. H. (2002). Existing and emerging endocrine therapies for breast cancer. Cancer Nursing, 25(Suppl. 2), 6S-11S.
    Fallowfield, L. (2004). Evolution of breast cancer treatment: Current options and quality-of-life considerations. European Journal of Oncology Nursing, 8(Suppl. 2), S75-S82. doi: 10.1016/j.ejon.2004.09.005
    Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004). Quality of life of postmenopausal women in Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. Journal of Clinical Oncology, 22, 4261-4271. doi: 10.1200/JCO.2004.08.029
    Fallowfield, L. J., Bliss, J. M., Porter, L. S., Price, M. H., Snowdon, C. F., Jones, S. E., … Hall, E. (2006). Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology, 24, 910-917. doi: 10.1200/JCO.2005.03.3654
    Fallowfield, L. J., Leaity, S. K., Howell, A., Benson, S., & Cella, D. (1999). Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Research and Treatment, 55, 189-199. doi: 10.1023/A:1006263818115
    Fellowes, D., Fallowfield, L. J., Saunders, C. M., & Houghton, J. (2001). Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for "well-tolerated" treatments? Breast Cancer Research and Treatment, 66, 73-81. doi: 10.1023/A:1010684903199
    Ferrell, B. R., Grant, M. M., Funk, B. M., Otis-Green, S. A., & Garcia, N. (1998). Quality of life in breast cancer survivors: Implications for developing support services. Oncology Nursing Forum, 25, 887-895.
    Gabbai, P., & Korem, D. (2002). Hormonal treatment for breast cancer: A challenge for nursing intervention initiative [in Hebrew]. Bama, 13, 111-115.
    Ganz, P. A., Greendale, G. A., Petersen, L., Zibecchi, L., Kahn, B., & Belin, T. R. (2000). Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. Journal of the National Cancer Institute, 92, 1054-1064. doi: 10.1093/jnci/92.13.1054
    Ganz, P. A., Rowland, J. H., Desmond, K., Meyerowitz, B. E., & Wyatt, G. E. (1998). Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. Journal of Clinical Oncology, 16, 501-514.
    Garreau, J. R., Delamelena, T., Walts, D., Karamlou, K., & Johnson, N. (2006). Side effects of aromatase inhibitors versus tamoxifen: The patient's perspective. American Journal of Surgery, 192, 496-498. doi: 10.1016/j.amjsurg.2006.06.018
    Glaus, A., Boehme, C., Thurlimann, B., Ruhstaller, T., Hsu Schmitz, S. F., Morant, R., … von Moss, R. (2006). Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Annals of Oncology, 17, 801-806. doi: 10.1093/annonc/mdl030
    Graf, M. C., & Geller, P. A. (2003). Treating hot flashes in breast cancer survivors: A review of alternative treatment to hormone replacement therapy. Clinical Journal of Oncology Nursing, 7, 637-640. doi: 10.1188/03.CJON.637-640
    Grana, G. (2003). New developments in endocrine therapy. Cancer Nursing, 26(Suppl. 6), 4S-9S. doi: 10.1097/00002820-200312001-00003
    Hallquist-Viale, P. (2005). Aromatase inhibitor agents in breast cancer. Evolving practices in hormonal therapy treatment. Oncology Nursing Forum, 32, 343-351. doi: 10.1188/05.ONF.343-351
    Hartman, A. R., & Helft, P. (2007). The ethics of cyp2d6 testing for patients considering tamoxifen. Retrieved from http://breast-cancer-research.com/content/9/103
    Harwood, K. V. (2004). Advances in endocrine therapy for breast cancer: Considering efficacy, safety, and quality of life. Clinical Journal of Oncology Nursing, 8, 629-637. doi: 10.1188/04.CJON.629-637
    Hassey-Dow, K. (2002). Existing and emerging endocrine therapies for breast cancer. Cancer Nursing, 25, 6-11.
    Israel Cancer Association. (2007). Breast cancer: Frequency/breast cancer [in Hebrew]. Retrieved from http://www.cancer.org.il/template
    Jonat, W., Kaufman, M., Sauerbrei, W., Blamey, R., Cuzick, J., Namer, M., … Zoladex Early Breast Cancer Research Association. (2002). Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. Research Association Study. Journal of Clinical Oncology, 20, 4628-4635. doi: 10.1200/JCO.2002.05.042
    Kimmick, G. G., Lovato, J., McQuellon, R., Robinson, E., & Muss, H. B. (2006). Randomized, double blind, placebo-controlled crossed study of sertraline (Zoloft®) for the treatment of hot flashes in women with early-stage breast cancer taking tamoxifen. Breast Journal, 12, 114-122. doi: 10.1111/j.1075-122X.2006.00218.x
    Knobf, M. T. (2001). The menopausal symptom experience in young mid-life women with breast cancer. Cancer Nursing, 24, 201-211. doi: 10.1097/00002820-200106000-00008
    Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, N. W., Vogal, V. G., & Lee, M. (2006). Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP study of tamoxifen and raloxifene (STAR) p-2 trial. JAMA, 295, 2742-2751.
    Leining, M. G., Gelber, S., Rosenberg, R., Przypyszny, M., Winer, E. P., & Partridge, A. H. (2006). Menopausal type symptoms in young breast cancer survivors. Annals of Oncology, 17, 1777-1782. doi: 10.1093/annonc/mdl299
    Leonard, R. C. F., Lee, L., & Harrison, M. E. (1996). Impact of side-effects associated with endocrine treatment for advanced breast cancer: Clinicians' and patients' perceptions. Breast, 5, 259-269. doi: 10.1016/S0960-9776(96)90021-1
    Loprinzi, C., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., … Christensen, B. J. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial. Lancet, 356, 2059-2063. doi: 10.1016/S0140-6736(00)03403-6
    McGinn, K., & Moore, J. (2001). Metastatic breast cancer: Understanding current management options. Oncology Nursing Forum, 28, 507-512.
    McGurk, R., Fallowfield, L., & Winters, Z. (2006). Information provision for patients by breast cancer teams about the side effects of hormone treatments. European Journal of Cancer, 42, 1760-1767. doi: 10.1016/j.ejca.2006.03.014
    Miaskowski, C., Shockney, L., & Chlebowski, R. T. (2008). Adherence to oral endocrine therapy for breast cancer: A nursing perspective. Clinical Journal of Oncology Nursing, 12, 213-221. doi: 10.1188/08.CJON.213-221
    Mouridsen, H. T. (2006). Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Current Medical Research and Opinion, 22, 1609-1621. doi: 10.1185/030079906X115667
    Mouridsen, H. T., Rose, C., Brodie, A. H., & Smith, I. E. (2003). Challenges in the endocrine management of breast cancer. Breast, 12(Suppl. 2), S2-S19. doi: 10.1016/S0960-9776(03)80158-3
    Palmieri, F. M., & Perez, E. A. (2003). Recent advances in adjuvant therapy for breast cancer. Seminars in Oncology Nursing, 19(4, Suppl. 2), 10-16. doi: 10.1053/j.soncn.2003.09.004
    Pennery, E. (2008). The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. European Journal of Oncology Nursing, 12, 233-243. doi: 10.1016/j.ejon.2008.01.007
    Schultz, P. N., Klein, M. J., Beck, M. L., Stava, C., & Sellin, R. V. (2005). Breast cancer: Relationship between menopausal symptoms, physiologic health effects of cancer treatment, and physical constraints on quality of life in long-term survivors. Journal of Clinical Nursing, 14, 204-211.
    Shilling, V., & Jenkins, V. (2007). Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. European Journal of Oncology Nursing, 11, 6-15. doi: 10.1016/j.ejon.2006.02.005
    Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., … Tannock, I. F. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183. doi: 10.1200/JCO.2003.01.119
    University of California, San Francisco, School of Nursing Symptom Management Faculty Group. (1994). A model for symptom management. Image: Journal of Nursing Scholarship, 26, 272-276. doi: 10.1111/j.1547-5069.1994.tb00333.x
    Viale, P. (2005). Aromatase inhibitor agents in breast cancer: Evolving practices in hormonal therapy treatment. Oncology Nursing Forum, 32, 343-353. doi: 10.1188/05.ONF.343-353
    Vigler, N., & Inbar, M. (2002). Hormonal treatment of breast cancer. Bama, 17, 52-56.
    Whelan, T. J., & Pritchard, K. I. (2006). Managing patients on endocrine therapy: Focus on quality-of-life issues. Clinical Cancer Research, 12(3, Pt. 2), 1056S-1060S. doi: 10.1158/1078-0432.CCR-05-2185
    Wilkinson, K. (2004). Anastrozole (Arimidex®). Clinical Journal of Oncology Nursing, 8, 87-88. doi: 10.1188/04.CJON.87-88
    Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., … Somerfield, M. R. (2005). American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. Journal of Clinical Oncology, 23, 619-629. doi: 10.1200/JCO.2005.09.121
    Winters, L., Habin, K., & Gallagher, J. (2007). Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clinical Journal of Oncology Nursing, 11, 433-439. doi: 10.1188/07.CJON.433-439
    Woods, W., Muss, H., Solin, L., & Olopade, O. (2005). Malignant tumors of the breast. In V. DeVita, S. Hellman, and S. Rosenberg (Eds.), Cancer-Principles and practice of oncology (7th ed., pp. 1415-1470). Philadelphia, PA: Lippincott Williams and Wilkins.